Regen BioPharma (Regen BioPharma) Other Long Term Assets : $-0.00 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Other Long Term Assets?

Regen BioPharma's other long-term assets for the quarter that ended in Mar. 2024 was $-0.00 Mil.

Regen BioPharma's quarterly other long-term assets increased from Sep. 2023 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($-0.00 Mil).

Regen BioPharma's annual other long-term assets increased from Sep. 2021 ($-0.00 Mil) to Sep. 2022 ($0.00 Mil) but then declined from Sep. 2022 ($0.00 Mil) to Sep. 2023 ($-0.00 Mil).

Regen BioPharma Other Long Term Assets Historical Data

The historical data trend for Regen BioPharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Other Long Term Assets Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Other Long Term Assets

Get a 7-Day Free Trial

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															-	-	-	-	-

Regen BioPharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.